CR20220153A - Derivados de 2–azaespiro [3.4] octano como agonistas de m4 - Google Patents

Derivados de 2–azaespiro [3.4] octano como agonistas de m4

Info

Publication number
CR20220153A
CR20220153A CR20220153A CR20220153A CR20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A CR 20220153 A CR20220153 A CR 20220153A
Authority
CR
Costa Rica
Prior art keywords
sup
agonists
azaspire
octane derivatives
formula
Prior art date
Application number
CR20220153A
Other languages
English (en)
Inventor
Amy Calhoun
Keith Jendza
Nancy Labbe-Giguere
Christopher G Thomson
Edward Charles Hall
James Neef
Daniel Steven Palacios
Ming Qian
Xin Chen
Kevin Matthew Gardinier
Michael David Shultz
Kate Yaping Wang
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20220153A publication Critical patent/CR20220153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) o su sal farmacéuticamente aceptable, en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, y R<sup>7</sup> se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
CR20220153A 2019-10-09 2020-10-07 Derivados de 2–azaespiro [3.4] octano como agonistas de m4 CR20220153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912986P 2019-10-09 2019-10-09
PCT/IB2020/059431 WO2021070091A1 (en) 2019-10-09 2020-10-07 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
CR20220153A true CR20220153A (es) 2022-05-03

Family

ID=72944206

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220153A CR20220153A (es) 2019-10-09 2020-10-07 Derivados de 2–azaespiro [3.4] octano como agonistas de m4

Country Status (23)

Country Link
US (3) US11485742B2 (es)
EP (1) EP4041737A1 (es)
JP (1) JP7349567B2 (es)
KR (1) KR102798432B1 (es)
CN (2) CN119390705A (es)
AR (1) AR120169A1 (es)
AU (1) AU2020364186B2 (es)
CA (1) CA3155589A1 (es)
CL (1) CL2022000892A1 (es)
CO (1) CO2022004391A2 (es)
CR (1) CR20220153A (es)
DO (1) DOP2022000075A (es)
EC (1) ECSP22027784A (es)
IL (1) IL291600A (es)
JO (1) JOP20220084A1 (es)
MX (1) MX2022004215A (es)
PE (1) PE20221454A1 (es)
PH (1) PH12022550860A1 (es)
PY (1) PY2061926A (es)
TW (1) TW202128703A (es)
UY (1) UY38907A (es)
WO (1) WO2021070091A1 (es)
ZA (1) ZA202202913B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021070090A1 (en) * 2019-10-09 2021-04-15 Novartis Ag 2-azaspiro[3.4]octane derivatives as m4 agonists
CN120344513A (zh) * 2022-09-16 2025-07-18 赛尔维治疗有限责任公司 M4活化剂/调节剂及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
US8927715B2 (en) 2006-08-25 2015-01-06 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
MX2011004340A (es) 2008-10-29 2011-05-23 Gruenenthal Gmbh Espiroaminas sustituidas.
KR20150116466A (ko) * 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
US20130230459A1 (en) 2010-11-08 2013-09-05 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGluR2 PET LIGANDS
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CN103732588B (zh) 2011-07-27 2016-10-12 南京奥昭生物科技有限公司 螺环分子作为蛋白激酶抑制剂
BR112015004826A2 (pt) 2012-09-07 2017-07-04 Zoetis Llc derivados espirocíclicos como agentes antiparasíticos
CN107098899B (zh) 2012-09-18 2019-09-06 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
SG11201606269WA (en) * 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
RU2017118562A (ru) 2014-10-31 2018-11-30 Индивиор ЮКей Лимитед Соединения-антагонисты дофаминового d3-рецептора
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB2540998A (en) 2015-08-04 2017-02-08 Phagenesis Ltd Catheter
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
TW202128703A (zh) 2021-08-01
CO2022004391A2 (es) 2022-04-29
KR102798432B1 (ko) 2025-04-22
CA3155589A1 (en) 2021-04-15
CL2022000892A1 (es) 2023-01-20
JP2022551853A (ja) 2022-12-14
ZA202202913B (en) 2023-06-28
EP4041737A1 (en) 2022-08-17
MX2022004215A (es) 2022-05-03
JOP20220084A1 (ar) 2022-04-06
KR20220079608A (ko) 2022-06-13
US20240140959A1 (en) 2024-05-02
CN114555606A (zh) 2022-05-27
AU2020364186B2 (en) 2023-11-30
US11485742B2 (en) 2022-11-01
DOP2022000075A (es) 2022-05-31
ECSP22027784A (es) 2022-05-31
JP7349567B2 (ja) 2023-09-22
WO2021070091A1 (en) 2021-04-15
AU2020364186A1 (en) 2022-04-21
CN114555606B (zh) 2024-10-01
CN119390705A (zh) 2025-02-07
US20220411435A1 (en) 2022-12-29
PY2061926A (es) 2021-08-12
UY38907A (es) 2021-05-31
AR120169A1 (es) 2022-02-02
US11820778B2 (en) 2023-11-21
PH12022550860A1 (en) 2023-06-14
IL291600A (en) 2022-05-01
PE20221454A1 (es) 2022-09-21
US20210130365A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JOP20210005B1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
BR112021021718A2 (pt) Moduladores de thr-ss e métodos de uso dos mesmos
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
EP4670791A3 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
PY1987737A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria
NZ796802A (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
MX2022002720A (es) Inhibidor de magl, procedimiento de preparacion y uso del mismo.
BR112022006157A2 (pt) Derivados de 5-oxa-2-azaespiro[3.4]octano como agonistas de m4
EA200970570A1 (ru) Макролидные соединения, обладающие противовоспалительной активностью
BR112022006386A2 (pt) Derivados de 2-azaspiro[3.4]octano como agonistas de m4
MX2024004273A (es) Derivado triciclico de pirimidina y aplicacion farmaceutica del mismo.
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7